KMR Group reports that the duration of clinical trials continues to hold steady or increase despite ongoing efforts by biopharmaceutical companies to reduce cycle times. KMR Group assessed cycle time trends for more than 6,000 Phase II/III clinical trials using proprietary industry data across 2Original Article
You may also like
Territory Sales Representative
Biopsy Sales Specialist – Miami, FL
Clinical Specialist
Medical Device Sales – Modesto, CA
Associate Territory Manager, Neurovascular –...
Aesthetic Surgical Rep Austin/San Antonio- Allergan...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.